LY 3185643Alternative Names: LY3185643
Latest Information Update: 20 Mar 2017
At a glance
- Originator Eli Lilly
- Mechanism of Action Glucagon receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hypoglycaemia
Most Recent Events
- 01 Mar 2017 Eli Lilly completes a phase I pharmacokinetics/pharmacodynamics trial in Healthy volunteers in Singapore (NCT02951780)
- 01 Nov 2016 Phase-I clinical trials in Hypoglycaemia (In volunteers) in Singapore (SC) (NCT02951780)
- 31 Oct 2016 Eli Lilly plans a phase I pharmacokinetics/pharmacodynamics trial in Healthy volunteers in Singapore (SC) (NCT02951780)